Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $400

Benzinga Newsdesk www.benzinga.com Neutral 51.7%

Neg 0% Neu 51.7% Pos 0%

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $370 to $400.